MRC/Arthritis Research UK funded project: Maximising Therapeutic Utility for Rheumatoid Arthritis (MATURA) programme
Getting treatment decisions right first time is key to better and more cost-effective outcomes for patients with Rheumatoid Arthritis (RA).
As RA is estimated to cost the public purse over £8 billion per year, optimising therapy using stratified medicine approaches – that is understanding which treatments are most suitable for different individuals – has the potential to result in a huge economic impact. Thus, the aim of MATURA is to move RA treatment from the current “trial and error” approach towards rational patient stratification by identifying predictors of response using a “multi-omic” approach.
Professor Anne Barton is leading MATURA work Strand 2, which aims to identify a blood-based biomarker signature to stratify RA patients according to the therapy to which they are most likely to respond. The biomarker profile investigation encompasses genetics, epigenetics, transcriptomics and proteomics along with demographic and other information. The samples have been collected from patients within MAHSC rheumatology centres at Central Manchester University Hospitals Foundation Trust, Salford Royal Foundation Trust, University Hospital of South Manchester Foundation Trust and across the UK as part of a multi-centre collaboration.